Sun Pharmaceuticals Industries Ltd: Intrinsic Value & Share Price Analysis

Q: What is the current share price and 52-week range of Sun Pharmaceuticals Industries Ltd?

Sun Pharmaceuticals Industries Ltd is trading at 1,824.00 as of 07 May 2026, with a FY2026-2027 high of 1,849 and low of 1,547. The stock is currently near its 52-week high. Market cap stands at 4,37,543 Cr..

Q: Is Sun Pharmaceuticals Industries Ltd financially healthy?

Key indicators: ROCE of 20.2 % indicates efficient capital utilization. Dividend yield is 0.88 %.

Fair Value

₹1,590.85Overvalued by 12.78%vs CMP ₹1,824.00

P/E (36.0) × ROE (16.9%) × BV (₹324.00) × DY (0.88%)

₹902.13Overvalued by 50.54%vs CMP ₹1,824.00

MoS: -102.2% (Negative)Confidence: 63/100 (Moderate)Models: 1 Under, 8 Over

Model	Category	Value	Weight	Signal
PE-ROE	Earnings	₹2,024.27	23%	Under (+11%)
Graham Number	Earnings	₹575.93	17%	Over (-68.4%)
Earnings Power	Earnings	₹313.60	11%	Over (-82.8%)
DCF	Cash Flow	₹1,098.50	11%	Over (-39.8%)
Net Asset Value	Assets	₹324.41	7%	Over (-82.2%)
EV/EBITDA	Enterprise	₹715.67	9%	Over (-60.8%)
Earnings Yield	Earnings	₹455.00	7%	Over (-75.1%)
ROCE Capital	Returns	₹405.57	7%	Over (-77.8%)
Revenue Multiple	Revenue	₹328.78	6%	Over (-82%)
Consensus (9 models)		₹902.13	100%	Overvalued

Key Drivers: EPS CAGR 27.2% lifts DCF — verify sustainability. | Wide model spread (₹314–₹2,024) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 27.2%

*Investments are subject to market risks

Analyst Summary

Sun Pharmaceuticals Industries Ltd operates in the Pharmaceuticals segment, current market price is ₹1,824.00, market cap is 4,37,543 Cr.. At a glance, stock P/E is 36.0, ROE is 16.9 %, ROCE is 20.2 %, book value is 324, dividend yield is 0.88 %. The latest intrinsic value estimate is ₹902.13, around 50.5% below the current price, so expectations may already be running ahead of this modelled fair value. On operating trend, latest reported sales are about ₹52,578 Cr versus the prior period change of 8.4%, while latest net profit is about ₹10,965 Cr with a prior-period change of 14.1%. The 52-week range shown on this page is 1,849/1,547, which helps frame where the current quote sits within its recent trading band. Business context: About the Company - Qualitative AnalysisSun Pharmaceutical Industries Ltd. is a Public Limited Listed company incorporated on 01/03/1993 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number…

This summary is generated from the stock page data available for Sun Pharmaceuticals Industries Ltd: Intrinsic Value & Share Price Analysis and is refreshed automatically when the underlying metrics change.

Investment Snapshot

Sun Pharmaceuticals Industries Ltd scores 65/100 (Average)

Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison

Stock Health87/100 · Strong

ROCE 20.2% ExcellentROE 16.9% GoodD/E 0.07 Low debtInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent

Smart Money45/100 · Moderate

FII holding down -1.84% (6mo) SellingDII holding up 2.14% MF buyingPromoter holding at 54.5% Stable

Earnings Quality50/100 · Moderate

OPM stable around 28% Steady

Quarterly Momentum50/100 · Moderate

Revenue (4Q): +10% YoY GrowingProfit (4Q): -5% YoY Declining

Industry Rank80/100 · Strong

P/E 36.0 vs industry 60.2 Cheaper than peersROCE 20.2% vs industry 16.5% Above peers3Y sales CAGR: 11% Moderate

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: May 5, 2026, 1:05 am

Market Cap	4,37,543 Cr.
Current Price	1,824
Intrinsic Value	₹902.13
High / Low	1,849/1,547
Stock P/E	36.0
Book Value	324
Dividend Yield	0.88 %
ROCE	20.2 %
ROE	16.9 %
Face Value	1.00
PEG Ratio	1.32

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Sun Pharmaceuticals Industries Ltd

Competitors

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
Sun Pharmaceuticals Industries Ltd	4,37,543 Cr.	1,824	1,849/1,547	36.0	324	0.88 %	20.2 %	16.9 %	1.00
Torrent Pharmaceuticals Ltd	1,43,681 Cr.	4,252	4,483/3,101	62.3	250	0.75 %	27.0 %	26.5 %	5.00
Cipla Ltd	1,07,814 Cr.	1,335	1,673/1,166	22.7	408	0.97 %	22.7 %	17.8 %	2.00
Lupin Ltd	1,07,452 Cr.	2,349	2,381/1,837	21.6	430	0.51 %	21.3 %	20.6 %	2.00
Dr Reddys Laboratories Ltd	1,07,433 Cr.	1,287	1,380/1,121	19.3	432	0.62 %	22.7 %	18.0 %	1.00
Industry Average	20,594.11 Cr	1,138.87		60.16	202.22	0.35%	16.48%	15.27%	6.10

All Competitor Stocks of Sun Pharmaceuticals Industries Ltd

Quarterly Result

Metric	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Sales	11,241	10,931	11,941	12,192	12,381	11,983	12,653	13,291	13,675	12,959	13,851	14,478	15,521
Expenses	8,237	8,129	8,609	9,013	8,904	8,948	9,045	9,352	9,666	9,243	9,550	9,951	10,572
Operating Profit	3,004	2,802	3,332	3,179	3,477	3,035	3,608	3,939	4,009	3,716	4,302	4,527	4,948
OPM %	27%	26%	28%	26%	28%	25%	29%	30%	29%	29%	31%	31%	32%
Other Income	174	202	-118	294	180	504	533	354	149	251	-354	470	89
Interest	46	93	81	49	35	74	62	69	52	49	75	100	78
Depreciation	660	672	651	633	622	650	655	626	631	664	701	730	732
Profit before tax	2,471	2,240	2,481	2,791	3,000	2,816	3,424	3,598	3,476	3,254	3,173	4,168	4,227
Tax %	11%	10%	19%	14%	14%	5%	16%	16%	16%	34%	27%	25%	20%
Net Profit	2,181	1,983	2,006	2,385	2,561	2,659	2,861	3,037	2,913	2,154	2,293	3,125	3,381
EPS in Rs	9.03	8.27	8.43	9.90	10.52	11.06	11.82	12.67	12.10	8.96	9.50	13.00	14.04

Last Updated: February 4, 2026, 1:16 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 26, 2026, 12:16 am

Metric	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	16,080	27,392	28,487	31,578	26,489	29,066	32,838	33,498	38,654	43,886	48,497	52,578	56,809
Expenses	9,078	19,498	20,313	21,476	20,858	22,689	25,855	25,028	28,397	32,235	35,479	37,464	39,316
Operating Profit	7,003	7,894	8,174	10,102	5,631	6,377	6,983	8,470	10,258	11,650	13,018	15,114	17,493
OPM %	44%	29%	29%	32%	21%	22%	21%	25%	27%	27%	27%	29%	31%
Other Income	-1,968	283	-42	610	-135	-258	382	-3,449	-3,505	459	865	1,444	457
Interest	44	579	523	400	518	555	303	141	127	172	238	231	302
Depreciation	409	1,195	1,038	1,265	1,500	1,753	2,053	2,080	2,144	2,529	2,557	2,575	2,826
Profit before tax	4,581	6,403	6,571	9,048	3,479	3,810	5,010	2,799	4,481	9,408	11,088	13,752	14,822
Tax %	15%	14%	14%	13%	26%	16%	16%	18%	24%	9%	13%	20%
Net Profit	3,879	5,476	5,658	7,846	2,542	3,208	4,172	2,272	3,389	8,513	9,610	10,965	10,953
EPS in Rs	15.17	21.92	18.89	29.03	8.73	11.11	15.69	12.10	13.64	35.32	39.91	45.55	45.50
Dividend Payout %	10%	14%	5%	12%	23%	25%	25%	62%	73%	33%	34%	35%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024	2024-2025
YoY Net Profit Growth (%)	41.17%	3.32%	38.67%	-67.60%	26.20%	30.05%	-45.54%	49.16%	151.20%	12.89%	14.10%
Change in YoY Net Profit Growth (%)	0.00%	-37.85%	35.35%	-106.27%	93.80%	3.85%	-75.59%	94.71%	102.03%	-138.31%	1.21%

Sun Pharmaceuticals Industries Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:	7%
5 Years:	10%
3 Years:	11%
TTM:	9%

Compounded Profit Growth
10 Years:	10%
5 Years:	24%
3 Years:	20%
TTM:	9%

Stock Price CAGR
10 Years:	6%
5 Years:	25%
3 Years:	21%
1 Year:	-13%

Return on Equity
10 Years:	14%
5 Years:	16%
3 Years:	17%
Last Year:	17%

Last Updated: September 5, 2025, 1:36 pm

Balance Sheet

Last Updated: December 4, 2025, 2:02 am

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Sep 2025
Equity Capital	207	207	241	240	240	240	240	240	240	240	240	240	240
Reserves	18,318	25,431	32,742	36,400	38,074	41,169	45,025	46,223	47,771	55,755	63,427	71,978	77,580
Borrowings	2,561	8,996	8,497	9,832	10,385	10,514	8,315	3,869	1,290	6,886	3,274	2,362	5,215
Other Liabilities	8,009	14,089	13,948	14,624	15,598	12,666	14,615	17,291	20,474	17,831	18,387	17,328	20,672
Total Liabilities	29,095	48,723	55,428	61,095	64,297	64,590	68,194	67,622	69,776	80,712	85,328	91,908	103,706
Fixed Assets	6,817	12,682	15,872	17,675	18,853	21,837	22,847	21,553	22,665	24,065	23,248	22,586	33,371
CWIP	842	2,039	2,175	2,801	2,465	1,411	1,220	1,567	1,287	4,973	5,354	6,644	1,355
Investments	2,786	2,716	1,830	1,192	7,143	7,903	10,143	9,612	12,849	14,824	15,026	18,354	19,543
Other Assets	18,650	31,286	35,550	39,427	35,837	33,439	33,984	34,890	32,975	36,849	41,700	44,324	49,438
Total Assets	29,095	48,723	55,428	61,095	64,297	64,590	68,194	67,622	69,776	80,712	85,328	91,908	103,706

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity +	3,959	5,616	6,686	7,082	3,907	2,196	6,555	6,170	8,985	4,959	12,135	14,072
Cash from Investing Activity +	-2,176	-1,502	-3,949	-4,186	-3,104	-310	-2,225	407	-5,556	-7,220	-763	-5,183
Cash from Financing Activity +	507	-1,187	-1,889	-2,285	-1,539	-2,731	-5,715	-5,980	-5,193	2,376	-6,710	-7,906
Net Cash Flow	2,290	2,927	848	611	-736	-844	-1,386	596	-1,765	115	4,662	983
Free Cash Flow	3,062	3,316	3,353	3,492	2,013	-966	5,105	5,097	7,550	2,895	9,964	12,005
CFO/OP	68%	93%	106%	90%	83%	48%	113%	85%	78%	56%	105%	96%

Free Cash Flow

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Free Cash Flow	5.00	-1.00	0.00	1.00	-5.00	-4.00	-2.00	5.00	9.00	5.00	10.00	13.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days	50	68	87	83	108	112	105	99	99	95	85	91
Inventory Days	410	307	370	307	338	366	311	378	315	360	338	348
Days Payable	174	178	207	197	234	192	142	167	158	194	194	210
Cash Conversion Cycle	286	197	251	193	212	285	274	310	255	261	229	228
Working Capital Days	71	-7	37	-4	-31	31	51	51	47	40	55	65
ROCE %	34%	23%	18%	20%	10%	10%	10%	13%	17%	16%	17%	20%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Promoters	54.48%	54.48%	54.48%	54.48%	54.48%	54.48%	54.48%	54.48%	54.48%	54.48%	54.48%	54.48%
FIIs	16.88%	16.48%	16.78%	17.08%	17.72%	17.23%	18.01%	18.04%	17.96%	17.26%	16.55%	16.12%
DIIs	19.18%	19.65%	19.56%	19.42%	18.71%	19.17%	18.48%	18.43%	18.58%	19.38%	20.12%	20.72%
Government	0.06%	0.09%	0.10%	0.11%	0.11%	0.11%	0.11%	0.11%	0.11%	0.11%	0.11%	0.11%
Public	9.38%	9.28%	9.05%	8.92%	8.97%	9.00%	8.89%	8.92%	8.86%	8.76%	8.72%	8.57%
No. of Shareholders	6,25,252	6,24,561	6,16,588	6,12,626	6,31,392	6,73,217	6,57,317	6,89,623	7,04,983	7,23,770	7,43,877	7,10,900

Shareholding Pattern Chart

No. of Shareholders

Sun Pharmaceuticals Industries Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund Name	No of Shares	AUM (%)	Amount Invested (Cr)	Previous Number of Shares	Previous Date	Percentage Change
ICICI Prudential Value Fund	15,466,098	4.44	2686.46	18,077,448	2026-03-23 10:36:30	-14.45%
ICICI Prudential Equity & Debt Fund	12,144,223	4.2	2109.45	14,178,073	2026-03-23 10:36:30	-14.35%
ICICI Prudential Large Cap Fund	11,153,571	2.5	1937.38	12,103,884	2026-03-23 10:36:30	-7.85%
HDFC Balanced Advantage Fund	8,346,339	1.35	1449.76	7,414,889	2026-02-23 04:02:03	12.56%
ICICI Prudential India Opportunities Fund	6,827,584	3.33	1185.95	7,527,584	2026-03-24 00:22:07	-9.3%
Nippon India Pharma Fund	6,256,349	13.08	1086.73	6,556,349	2025-12-08 04:19:42	-4.58%
ICICI Prudential Multi Asset Fund	5,931,574	1.24	1030.31	5,960,937	2026-02-23 04:02:03	-0.49%
ICICI Prudential ELSS Tax Saver Fund	5,292,223	6.4	919.26	5,105,969	2026-02-23 04:02:03	3.65%
ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund	4,389,473	11.21	762.45	4,673,560	2026-03-23 10:36:30	-6.08%
ICICI Prudential Balanced Advantage Fund	3,745,554	0.91	650.6	4,827,054	2026-03-23 10:36:30	-22.4%

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21
FaceValue	1.00	1.00	1.00	1.00	1.00
Basic EPS (Rs.)	45.60	39.90	35.30	13.60	12.10
Diluted EPS (Rs.)	45.60	39.90	35.30	13.60	12.10
Cash EPS (Rs.)	56.50	50.87	46.22	23.13	18.19
Book Value[Excl.RevalReserv]/Share (Rs.)	301.00	265.36	247.22	212.84	206.23
Book Value[Incl.RevalReserv]/Share (Rs.)	301.00	265.36	247.22	212.84	206.23
Revenue From Operations / Share (Rs.)	219.14	202.13	182.91	161.11	139.62
PBDIT / Share (Rs.)	71.84	59.92	51.19	47.18	38.87
PBIT / Share (Rs.)	61.11	49.27	40.64	38.24	30.20
PBT / Share (Rs.)	57.32	46.21	39.21	18.68	11.67
Net Profit / Share (Rs.)	45.76	40.21	35.68	14.20	9.52
NP After MI And SOA / Share (Rs.)	45.55	39.91	35.32	13.64	12.10
PBDIT Margin (%)	32.78	29.64	27.98	29.28	27.84
PBIT Margin (%)	27.88	24.37	22.22	23.73	21.63
PBT Margin (%)	26.15	22.86	21.43	11.59	8.35
Net Profit Margin (%)	20.88	19.89	19.50	8.81	6.82
NP After MI And SOA Margin (%)	20.78	19.74	19.30	8.46	8.66
Return on Networth / Equity (%)	15.13	15.04	15.13	6.81	6.24
Return on Capital Employeed (%)	19.83	17.26	16.02	17.44	14.06
Return On Assets (%)	11.86	11.20	10.49	4.68	4.29
Long Term Debt / Equity (X)	0.00	0.00	0.00	0.00	0.01
Total Debt / Equity (X)	0.02	0.04	0.11	0.01	0.07
Asset Turnover Ratio (%)	0.59	0.58	0.58	0.56	0.49
Current Ratio (X)	2.89	2.56	2.00	2.04	1.89
Quick Ratio (X)	2.33	1.98	1.48	1.51	1.33
Inventory Turnover Ratio (X)	5.23	4.76	0.79	0.78	0.72
Dividend Payout Ratio (NP) (%)	33.06	30.26	29.73	65.96	53.68
Dividend Payout Ratio (CP) (%)	26.76	23.88	22.89	39.85	31.28
Earning Retention Ratio (%)	66.94	69.74	70.27	34.04	46.32
Cash Earning Retention Ratio (%)	73.24	76.12	77.11	60.15	68.72
Interest Coverage Ratio (X)	74.50	60.29	71.40	88.88	65.95
Interest Coverage Ratio (Post Tax) (X)	51.39	43.53	51.77	63.60	47.60
Enterprise Value (Cr.)	407192.46	384570.80	239622.86	218440.19	143296.74
EV / Net Operating Revenue (X)	7.74	7.93	5.46	5.65	4.28
EV / EBITDA (X)	23.62	26.75	19.51	19.30	15.36
MarketCap / Net Operating Revenue (X)	7.92	8.02	5.37	5.68	4.28
Retention Ratios (%)	66.93	69.73	70.26	34.03	46.31
Price / BV (X)	5.77	6.11	4.21	4.57	3.09
Price / Net Operating Revenue (X)	7.92	8.02	5.37	5.68	4.28
EarningsYield	0.02	0.02	0.03	0.01	0.02

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Sun Pharmaceutical Industries Ltd. is a Public Limited Listed company incorporated on 01/03/1993 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is L24230GJ1993PLC019050 and registration number is 019050. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 23003.33 Cr. and Equity Capital is Rs. 239.93 Cr. for the Year ended 31/03/2025.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	Sun Pharma Advanced Research Centre (SPARC), Tandalja, Vadodra Gujarat 390012	Contact not found

Management
Name	Position Held
Mr. Dilip S Shanghvi	Chairman & Managing Director
Mr. Aalok D Shanghvi	Whole Time Director & COO
Ms. Vidhi D Shanghvi	Whole Time Director
Mr. Sudhir V Valia	Non Exe.Non Ind.Director
Dr. Pawan Goenka	Lead Independent Director
Mr. Rama Bijapurkar	Independent Director
Mr. Gautam Doshi	Independent Director
Mr. Rolf Hoffmann	Independent Director

FAQ

What is the intrinsic value of Sun Pharmaceuticals Industries Ltd and is it undervalued?

As of 07 May 2026, Sun Pharmaceuticals Industries Ltd's intrinsic value is ₹902.13, which is 50.54% lower than the current market price of ₹1,824.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (16.9 %), book value (₹324), dividend yield (0.88 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Sun Pharmaceuticals Industries Ltd?

Sun Pharmaceuticals Industries Ltd is trading at ₹1,824.00 as of 07 May 2026, with a FY2026-2027 high of ₹1,849 and low of ₹1,547. The stock is currently near its 52-week high. Market cap stands at ₹4,37,543 Cr..

How does Sun Pharmaceuticals Industries Ltd's P/E ratio compare to its industry?

Sun Pharmaceuticals Industries Ltd has a P/E ratio of 36.0, which is below the industry average of 60.16. This is broadly in line with or below the industry average.

Is Sun Pharmaceuticals Industries Ltd financially healthy?

Key indicators for Sun Pharmaceuticals Industries Ltd: ROCE of 20.2 % indicates efficient capital utilization; ROE of 16.9 % shows strong shareholder returns. Dividend yield is 0.88 %.

Is Sun Pharmaceuticals Industries Ltd profitable and how is the profit trend?

Sun Pharmaceuticals Industries Ltd reported a net profit of ₹10,965 Cr in Mar 2025 on revenue of ₹52,578 Cr. Compared to ₹3,389 Cr in Mar 2022, the net profit shows an improving trend.

Does Sun Pharmaceuticals Industries Ltd pay dividends?

Sun Pharmaceuticals Industries Ltd has a dividend yield of 0.88 % at the current price of ₹1,824.00. The company pays dividends, though the yield is modest.